Loading clinical trials...
Loading clinical trials...
Phase I/II Study of Ixazomib in Combination with Pomalidomide, Clarithromycin and Dexamethasone (PiC-D) in Patients with Double Refractory Multiple Myeloma
Conditions
Interventions
Clarithromycin
Dexamethasone
+2 more
Locations
3
United States
University of California San Diego
La Jolla, California, United States
University of California Irvine
Orange, California, United States
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Start Date
October 1, 2015
Primary Completion Date
August 1, 2025
Completion Date
December 1, 2025
Last Updated
September 19, 2024
NCT06179888
NCT06152575
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
Joseph Tuscano
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions